Journal of Clinical Medicine (Feb 2021)

Aberrant Expression of <i>TLR2</i>, <i>TLR7</i>, <i>TLR9</i>, Splicing Variants of <i>TLR4</i> and <i>MYD88</i> in Chronic Lymphocytic Leukemia Patients

  • Katarzyna Skorka,
  • Paulina Wlasiuk,
  • Agnieszka Karczmarczyk,
  • Krzysztof Giannopoulos

DOI
https://doi.org/10.3390/jcm10040867
Journal volume & issue
Vol. 10, no. 4
p. 867

Abstract

Read online

Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvironment. Myd88 is involved in activation NF-κB through TLRs downstream signaling, hence in the current study we provided, for the first time, a complex characterization of expression of TLR2, TLR4, TLR7, TLR9, and MYD88 as well as their splicing forms in two distinct compartments of the microenvironment of chronic lymphocytic leukemia (CLL): peripheral blood and bone marrow. We found correlations between MYD88 and TLRs expressions in both compartments, indicating their relevant cooperation in CLL. The MYD88 expression was higher in CLL patients compared to healthy volunteers (HVs) (0.1780 vs. 0.128, p TLR4(3) expression compared to high level of TLR4(3) expression in bone marrow (13 months vs. 48 months, p = 0.0207). We suggest that TLRs expression is differentially regulated in CLL but is similarly shared between two distinct compartments of the microenvironment.

Keywords